SURMOUNT-3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
The archive — 2024
Page 49 of 68 of this archive, newest first.
SURMOUNT-OSA misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Dual, triple, co-formulated: a taxonomy the coverage keeps collapsing
Head-to-head data exists for some of these comparisons and not for others. This piece says which.
Four ways a peptide comes apart
We describe each pathway in enough chemical detail to explain why it is invisible to the method the trade uses, because that is the part which has practical consequences.
Spain caps tirzepatide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What changed at WWB in April, and what the company says prompted it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The one place the insulin literature and this class agree completely
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
A schedule that bends does not break
Every major phase 3 protocol in this class allowed escalation to be delayed for tolerability. Almost no product label explains the mechanics of doing so.
Australia health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
REWIND misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 21 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Twenty-eight days is a number from somebody else’s product
We set out what is known, what is inferred and what is simply assumed about the fortnight after a vial is opened.
The submitted sample: the weakest link in the whole system
Every third-party report in this market describes a sample somebody chose to send. That choice is outside the laboratory’s control and outside its records.
Why the bone question is harder than the muscle question
What the Journal would want measured before treating this as settled in either direction.
Homopeptide names the synthesis and fill sites behind its catalogue
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Independent analysis puts a WXT semaglutide lot at 98.0%, against 95.7% on the certificate
The result is unremarkable. What the report states alongside it is not.
Inspectors cite the online reseller trading as Adamant Research Supply over sterility assurance
The observation that closes a facility is rarely the dramatic one.
The 23-day notice: how a compounding wind-down works in the United Kingdom
The document is four pages. Three of them are about dates.
The mechanism behind the mechanism
A single drug producing both constipation and diarrhoea looks contradictory until the motility data is read properly.
STEP 2 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
VendorInvestigate result on a Wuhan orforglipron lot lands 3.8 points above the supplier’s stated figure
The supplier confirmed the determination and supplied the method behind its own figure inside a week.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to South Africa after 14 consecutive customs detentions
The route did not close because of a rule about peptides.
What STEP 3 measured, and what it was never powered to detect
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
A document, not a test: what a certificate actually is
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
What the new Ireland guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Guangzhou: 10 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Inspectors cite the consolidator trading as Meridian Freight Partners over sterility assurance
The observation that closes a facility is rarely the dramatic one.